Meningococcal disease is one of the fastest-killing bacterial infections in medicine. A person can wake up with a fever and headache and be dead within 24 hours. Even with appropriate antibiotic treatment, the case-fatality rate is 10 to 15 percent — meaning one in ten people who develop the disease die from it regardless of how quickly treatment begins. Of those who survive, 20 percent are left with permanent disability: amputated limbs, hearing loss, neurological damage, and skin necrosis from the blood vessel damage the bacteria cause.
In the United States, this disease has been surging since 2021, and the 2025 case count has put the trend in stark relief. CDC surveillance data updated June 2026 confirm that 463 confirmed and probable meningococcal disease cases were reported in 2025 — the second-highest annual total in the United States since 2014. The 2024 tally was 503 cases, the highest in over a decade. Before the pandemic era, when social distancing and masking suppressed transmission of many respiratory pathogens, annual U.S. meningococcal disease case counts had declined to 250 to 350 per year. The current surge represents a reversal of two decades of hard-won progress.
